Attainment of LDL-cholesterol treatment goals in patients with familial hypercholesterolemia: 5-year SAFEHEART registry follow-up

Journal of the American College of Cardiology

Volumn 67, Issue 11, 2016, Pages 1278-1285

  Perez De Isla, Leopoldo ^a,b   Alonso, Rodrigo ^b,c   Watts, Gerald F ^d,e   Mata, Nelva ^b,f   Saltijeral Cerezo, Adriana ^b,g   Muñiz, Ovidio ^h   Fuentes, Francisco ⁱ   Diaz Diaz, José Luís ^j   De Andrés, Raimundo ^k   Zambón, Daniel ^l   Rubio Marin, Patricia ^m   Barba Romero, Miguel A ⁿ   Saenz, Pedro ^o   Sanchez Muñoz Torrero, Juan F ^p   Martinez Faedo, Ceferino ^q   Miramontes Gonzalez, José P ^r   Badimón, Lina ^s   Mata, Pedro ^a,b   Aguado, Rocío ⁿ   Almagro, Fátima ⁿ   Arrieta, Francisco ⁿ   Barba, Miguel Ángel ⁿ   Brea, Ángel ⁿ   Cepeda, Jose María ⁿ   Díaz, Gonzalo ⁿ   Díaz, José L ⁿ   Garrido, Juan Antonio ⁿ   Irigoyen, Luis ⁿ   Manjón, Laura ⁿ   Martin, Alberto ⁿ   Piedecausa, Mar ⁿ   Mauri, Marta ⁿ   Miramontes, Pablo ⁿ   Pereyra, Francisca ⁿ   Pérez, Leire ⁿ   Pintó, Xavier ⁿ   Pujante, Pedro ⁿ   Ruiz, Enrique ⁿ   Sánchez, Juan F ⁿ   Vidal, Jose I ⁿ   Argüeso, Rosa ⁿ   more..

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b Medicina Interna   (Spain)

^c CLÍNICA LAS CONDES   (Chile)

^d ROYAL PERTH HOSPITAL   (Australia)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^f Madrid Regional Authority   (Spain)

^g España Electronic address: juanmartinnav hotmailcom   (Spain)

^h HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

ⁱ HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^j Hospital Abente y Lago   (Spain)

^k Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^l HOSPITAL CLÍNIC   (Spain)

^m HOSPITAL DE JEREZ   (Spain)

ⁿ Complejo Hospitalario Universitario ^*

^o Hospital de Merida   (Spain)

^p HOSPITAL SAN PEDRO DE ALCÁNTARA   (Spain)

^q Hospital Central   (Spain)

^r Hospital Univeritario   (Spain)

^s Institut Català de Ciències Cardiovasculars   (Spain)

more..

Author keywords

cardiovascular disease; LDL receptor mutations; lipid lowering therapy; low density lipoprotein cholesterol

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; EZETIMIBE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; BIOLOGICAL MARKER; HYPOCHOLESTEROLEMIC AGENT;

ADULT; ALLELE; ARTICLE; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DISEASE REGISTRY; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; FOLLOW UP; GENE MUTATION; GOAL ATTAINMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SPAIN; ADOLESCENT; BLOOD; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DOSE RESPONSE; HYPERLIPOPROTEINEMIA TYPE II; MIDDLE AGED; REGISTER; TIME FACTOR; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; ANTICHOLESTEREMIC AGENTS; ATORVASTATIN CALCIUM; BIOMARKERS; CHOLESTEROL, LDL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; EZETIMIBE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REGISTRIES; ROSUVASTATIN CALCIUM; SPAIN; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84962921192     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2016.01.008     Document Type: Article

References (25)

1. J.L. Goldstein, H.H. Hobbs, and M.S. Brown Familial hypercholesterolemia C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle, The Metabolic and Molecular Basis of Inherited Disease Volume II 2001 McGraw-Hill New York, NY 2863 2913
2. Scientific Steering Committee on behalf of the Simon Broome Register Group: Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management Atherosclerosis 142 1999 105 112
3. A. Neil, J. Cooper, J. Betteridge, and et al. Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study Eur Heart J 29 2008 2625 2633
4. J. Versmissen, D.M. Oosterveer, M. Yazdanpanah, and et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study BMJ 337 2008 a2423
5. R. Alonso, N. Mata, S. Castillo, and et al. Cardiovascular disease in familial hypercholesterolaemia: influence of low-density lipoprotein receptor mutation type and classic risk factors Atherosclerosis 200 2008 315 321
6. A.C. Jansen, S. van Wissen, J. Defesche, and et al. Phenotypic variability in familial hypercholesterolaemia: an update Curr Opin Lipidol 13 2002 165 171
7. R. Alonso, E. Andres, N. Mata, and et al. Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation J Am Coll Cardiol 63 2014 1982 1989
8. A.H. Pijlman, R. Huijgen, S.N. Verhagen, and et al. Evaluation of cholesterol lowering treatment of patients with Familial hypercholesterolemia: a large cross sectional study in the Netherlands Atherosclerosis 209 2010 189 194
9. B.G. Nordestgaard, M.J. Chapman, S.E. Humphries, and et al. for the European Atherosclerosis Society Consensus Panel. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease Eur Heart J 34 2013 3478 3490
10. G.F. Watts, S. Gidding, A.S. Wierzbicki, and et al. Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation Int J Cardiol 171 2014 309 325
11. V.J. Bufalino, F.A. Masoudi, S.K. Stranne, and et al. The American Heart Association's recommendations for expanding the applications of existing and future clinical registries: a policy statement from the American Heart Association Circulation 123 2011 2167 2179
12. E. Hammond, G.F. Watts, Y. Rubinstein, and et al. Role of international registries in enhancing the care of familial hypercholesterolaemia Int J Evid Based Healthc 11 2013 134 139
13. N. Mata, R. Alonso, L. Badimón, and et al. Clinical characteristics and evaluation of LDL-cholesterol treatment of the Spanish Familial Hypercholesterolemia Longitudinal Cohort Study (SAFEHEART) Lipids Health Dis 10 2011 94
14. A.S. Wierzbicki, S.E. Humphries, R. Minhas Guideline Development Group Familial hypercholesterolaemia: summary of NICE guidance BMJ 337 2008 a1095
15. R. Alonso, J.C. Defesche, D. Tejedor, and et al. Genetic diagnosis of familial hypercholesterolemia using a DNA-array based platform Clin Biochem 42 2009 899 903
16. N.J. Stone, J.G. Robinson, A.H. Lichtenstein, et al. for the American College of Cardiology/American Heart Association Task Force on Practice Guidelines 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 63 2014 2889 2934
17. R. Alonso, P. Mata, D. Zambón, and et al. Early diagnosis and treatment of familial hypercholesterolemia: improving patient outcomes Expert Rev Cardiovasc Ther 11 2013 327 342
18. T.P. Leren, and K.E. Berge Subjects with molecularly defined familial hypercholesterolemia or familial defective apoB-100 are not being adequately treated PLos ONE 6 2011 e16721
19. S. Béliard, V. Carreau, A. Carrié, and et al. Improvement in LDL-cholesterol levels of patients with familial hypercholesterolemia: can we do better? Analysis of results obtained during the past two decades in 1669 French subjects Atherosclerosis 234 2014 136 141
20. P.C. Santos, A.C. Morgan, C.E. Jannes, and et al. Presence and type of low density lipoprotein receptor (LDLR) mutation influences the lipid profile and response to lipid-lowering therapy in Brazilian patients with heterozygous familial hypercholesterolemia Atherosclerosis 233 2014 206 210
21. E. Stein, S. Stender, P. Mata, et al. for the Ezetimibe Study Group Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin Am Heart J 148 2004 447 455
22. C.P. Cannon, M.A. Blazing, R.P. Giugliano, and et al. Ezetimibe added to statin therapy after acute coronary syndromes N Engl J Med 372 2015 2387 2397
23. R.P. Giugliano, and M.S. Sabatine Are PCSK9 inhibitors the next breakthrough in the cardiovascular field? J Am Coll Cardiol 65 2015 2638 2651
24. D.A. Bell, J. Garton-Smith, A. Vickery, and et al. Familial hypercholesterolaemia in primary care: knowledge and practices among general practitioners in Western Australia Heart Lung Circ 23 2014 309 313
25. A.W. Vickery, D. Bell, J. Garton-Smith, and et al. Optimising the detection and management of familial hypercholesterolaemia: central role of primary care and its integration with specialist services Heart Lung Circ 23 2014 1158 1164